文献速递中医内科中药与中成药合理使用

大柴胡汤通过调控MAPK信号通路缓解慢性胰腺炎:网络药理学与实验验证

Dachaihu Decoction alleviates chronic pancreatitis by regulating MAPK signaling pathway: Insights from network pharmacology and experimental validation.
PubMed 文献 · J Ethnopharmacol · 2024-09-20

该研究结合网络药理学、分子对接、转录组学和动物实验,探讨大柴胡汤治疗慢性胰腺炎(CP)的机制。小鼠CP模型显示大柴胡汤改善胰腺腺泡细胞损伤、炎症和纤维化,网络药理学识别385个相关靶点,KEGG富集提示MAPK通路,实验证实大柴胡汤及黄芩苷抑制胰腺组织p-P38、p-JNK、p-ERK表达。

要点

  • 大柴胡汤可减轻CP小鼠胰腺腺泡细胞损伤、炎症与纤维化。
  • 其机制可能与抑制胰腺MAPK信号通路(p-P38、p-JNK、p-ERK)相关。
  • 黄芩苷是大柴胡汤中有效成分,可降低胰腺星状细胞和巨噬细胞MAPK关键蛋白表达。

核心结论

  • 大柴胡汤对慢性胰腺炎具有治疗作用,可能成为延缓CP进展的潜在药物。
  • 大柴胡汤缓解胰腺炎症细胞浸润和纤维化可能与调控MAPK信号通路有关。

研究设计与样本

  • 采用网络药理学、分子对接、转录组分析和动物实验相结合的方法。
  • 使用雨蛙素诱导小鼠慢性胰腺炎模型,大柴胡汤灌胃给药评估疗效。
  • 收集胰腺组织进行转录组分析,并用分子对接初步验证。
  • 基于预测结果进行体内和体外验证,包括动物实验、人胰腺星状细胞系(hPSCs)和巨噬细胞系RAW264.7实验。

主要发现

  • 大柴胡汤改善CP小鼠胰腺腺泡细胞损伤、胰腺炎症和纤维化。
  • 网络药理学识别大柴胡汤治疗CP的385个潜在靶点。
  • KEGG通路分析显示大柴胡汤治疗CP可能与MAPK信号通路相关。
  • 转录组数据证实大柴胡汤抑制CP胰腺MAPK信号通路。

关键数值与推荐

  • 网络药理学识别385个大柴胡汤与CP相关的潜在靶点。
  • KEGG通路分析提示MAPK信号通路参与大柴胡汤治疗CP。
  • 动物实验显示大柴胡汤降低胰腺组织p-P38、p-JNK、p-ERK表达。
  • 黄芩苷降低hPSCs和RAW264.7中MAPK通路关键蛋白表达。

临床怎么用

  • 大柴胡汤可作为少阳阳明合病所致慢性胰腺炎的候选方剂。
  • 临床关注大柴胡汤及其活性成分黄芩苷对MAPK通路的调控作用。
  • 未来可进一步开展临床研究验证大柴胡汤治疗CP的疗效与安全性。

局限性

  • 研究基于小鼠模型和细胞实验,尚未在人体中验证。
  • 原文未报告样本量、具体剂量、P值等详细数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

ETHNOPHARMACOLOGICAL RELEVANCE: Chronic pancreatitis (CP), a syndrome characterized by inflammatory fibrosis, can impair both the internal and external secretory functions of the pancreas. The global incidence of this disease is gradually increasing. However, the exact pathogenesis remains unclear, resulting in a lack of targeted clinical therapies. According to the principles of traditional Chinese medicine, CP can be attributed to Shaoyang and Yangming syndromes, which manifest as abdominal pain and hypochondriac distension. Dachaihu Decoction (DCHD) is a classic formula from the "Treatise on Febrile and Miscellaneous Disease." It is frequently prescribed for conditions associated with combined Shaoyang and Yangming syndromes. However, the specific mechanisms by which DCHD prevents and treats CP remain unclear and require further investigation. AIM OF THE STUDY: Using a holistic methodology, including network pharmacology, molecular docking, transcriptomic profiling, and animal experimentation, we explored the potential therapeutic mechanisms of DCHD in CP. MATERIALS AND METHODS: In a mouse model, caerulein was used to induce CP, and DCHD was administered via gastric lavage to assess its therapeutic effect on pancreatic injury caused by caerulein-induced CP. Subsequently, pancreatic tissues were collected for transcriptomic analysis. Screening of DCHD-active ingredient-target pathways for CP treatment was conducted using network pharmacology and further preliminary validation was performed using molecular docking techniques. Additionally, in vivo and in vitro validation was conducted using animal and cells experiments based on the predicted results. RESULTS: Our findings suggest that DCHD ameliorates pancreatic acinar cell injury, pancreatic inflammation, and fibrosis in mice with CP. Network pharmacology identified 385 potential targets of DCHD associated with CP. Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis revealed that the therapeutic effect of DCHD on CP may be linked to the mitogen-activated protein kinase (MAPK) signaling pathway. Transcriptomic data supported this finding, as it confirmed that DCHD inhibited the pancreatic MAPK signaling pathway in CP. Molecular docking studies further revealed that the top ten active components of DCHD exhibited strong docking activity with key molecules within the MAPK signaling pathway. Finally, animal experiments confirmed that DCHD effectively reduced the phosphorylation of P38, Jun N-terminal kinase (JNK), and extracellular signal-regulated kinase (ERK) in pancreatic tissues. In addition, the expression of p-P38, p-JNK, and p-ERK was reduced in pancreatic stellate cells and macrophages in the DCHD group. We further treated CP mice, human pancreatic stellate cell line (hPSCs), and macrophage cell line RAW264.7 with the active component baicalin from DCHD, and found that baicalin effectively reduced pancreatic damage in CP. Additionally, the expression of key proteins in the MAPK signaling pathway was significantly decreased in both hPSCs and RAW264.7. CONCLUSION: In summary, DCHD plays an important role in the treatment of chronic pancreatitis, and it may become a promising drug against the progression of CP. The role of DCHD in alleviating pancreatic inflammatory cell infiltration and fibrosis may be related to the regulation of the MAPK signaling pathway.

来源:J Ethnopharmacol,查看原文。版权归原作者所有。

引用

  1. Li X, Yan Z, Cao X, et al. Dachaihu Decoction alleviates chronic pancreatitis by regulating MAPK signaling pathway: Insights from network pharmacology and experimental validation. J Ethnopharmacol. 2024. PMID: 39306212. doi:10.1016/j.jep.2024.118833

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。